Price
No data yet.
Social Signal Score
Analyst Ratings
25 analystsRevenue
$211.03M+536.17%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas William Burns
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1,094
- Beta
- 0.69
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 31.44
Financials
Revenue
$211.03M+536.2%Net Income
$2.02M+1406.0%EBITDA
$12.36M+612.9%Free Cash Flow
$36.49M+2852.3%EPS (diluted)
$0.03+733.3%Shares Outstanding (diluted)
61.20M+64.6%Operating Expenses
$179.04MCash & Debt
$336.70MReturn of Capital
$0.00Revenue by Segment (annual)
$236.98MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $507.44M | $-187.69M | $-3.28 |
| 2024 | $383.48M | $-146.37M | $-2.77 |
| 2023 | $314.71M | $-134.66M | $-2.78 |
| 2022 | $282.86M | $-99.19M | $-2.09 |
| 2021 | $294.01M | $-49.59M | $-1.07 |
| 2020 | $224.96M | $-120.35M | $-2.70 |
| 2019 | $236.98M | $15.42M | $0.41 |
| 2018 | $181.28M | $-12.95M | $-0.37 |
| 2017 | $159.25M | $-92.0K | $-0.00 |
| 2016 | $114.40M | $4.52M | $0.14 |
| 2015 | $71.70M | $-37.24M | $-2.13 |
| 2014 | $45.59M | $-12.13M | $-0.49 |
| 2013 | $20.95M | $-12.64M | $-0.51 |
| 2012 | $2.43M | $-19.33M | $-9.73 |
Valuation
GKOShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
75+25.00%Social Signal Score
Mentions (21)
- Newszacks.com·4d ago·Positive
What Drove Glaukos Stock's 48% Rally Since the End of September? Glaukos shares have surged 48.2% since September-end, fueled by strong Q3 results, raised sales guidance, Epioxa and iDose TR growth, and positive clinical data.
View source ↗ - Newsfool.com·24d ago·Neutral
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction Glaukos raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 target of $1 billion, after third-quarter sales jumped 58% to $211.0 million. Profit is thinner than the adjusted figures suggest.
View source ↗ - News (RSS)zerohedge·24d ago·Neutral
…full year beat the average analyst estimate.Fortinet (FTNT) plunges 26% after the security software company gave a disappointing outlook for service revenue.Glaukos (GKOS) is up 15% after the eye-focused medical device maker boosted its net sales guidance for the full year. The guidance surpassed Wall Street’s expectations.Marvell Technology (MRVL) falls 11% as the company is said to be in advanced talks to buy data center optics maker Lumentum Holdings (LITE), according to people familiar with …
View source ↗ - Newsbenzinga.com·24d ago·Neutral
Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket Shares of Glaukos Corp (NYSE:GKOS) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·25d ago·Negative
Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsmarketbeat.com·25d ago·Neutral
Glaukos Q3 Earnings Call Highlights Glaukos NYSE: GKOS reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment. The company raised its full-year 2026 revenue outlook and introduced a preliminary target of $1 billion in revenue for 2027.
View source ↗ - Newszacks.com·39d ago·Positive
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
View source ↗ - News (RSS)seekingalpha·42d ago·Neutral
Glaukos: Steep Premium For New Therapies And Growth
View source ↗ - News (Marketaux)seekingalpha.com·42d ago·Positive
Glaukos: Steep Premium For New Therapies And Growth (NYSE:GKOS) Glaukos: Steep Premium For New Therapies And Growth (NYSE:GKOS)
View source ↗ - News (RSS)seekingalpha·43d ago·Positive
Glaukos: The Second J-Code Rewrites The Risk Math
View source ↗ - Newsseekingalpha.com·43d ago·Neutral
Glaukos: The Second J-Code Rewrites The Risk Math Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.
View source ↗ - News (RSS)seekingalpha·44d ago·Neutral
Glaukos' iDose TR meets primary goal in phase 4 trial
View source ↗ - Newszacks.com·44d ago·Neutral
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
View source ↗ - Newsbenzinga.com·44d ago·Negative
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study.
View source ↗ - News (RSS)businessinsider·45d ago·Negative
Glaukos slips as insider selling overshadows positive trial data for eye therapy
View source ↗ - News (Marketaux)seekingalpha.com·45d ago·Negative
Glaukos stock slips after insider selling (GKOS:NYSE) Despite announcing positive data from a [+240 characters]
View source ↗ - Newsbenzinga.com·45d ago·Neutral
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while simultaneously securing an exclusive licensing deal to broaden its pipeline of retinal disease therapies.
View source ↗ - Newszacks.com·59d ago·Positive
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
View source ↗ - Newszacks.com·95d ago·Positive
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
View source ↗ - Newsbusinesswire.com·95d ago·Neutral
Glaukos Announces Participation in Wells Fargo Healthcare Conference ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for…
View source ↗
Earnings
Tue, Feb 16(in 3 months)
Consensus estimate $0.50 per share
Typical surprise +33.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 28$0.47 vs $-0.10beat
- Wed, Jul 29$-0.14 vs $-0.21beat
- Wed, Apr 29$-0.18 vs $-0.30beat
- Tue, Feb 17$-0.28 vs $-0.22miss
- Wed, Oct 29$-0.16 vs $-0.27beat
- Wed, Jul 30$-0.24 vs $-0.26beat
Estimates and results for GKOS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GKOS officers and directors.
- Bought
- —
- Sold
- $83.2m
0 trades
59 trades
- Burns Thomas Williamsold
- Burns Thomas Williamsold
- Burns Thomas Williamsold
- Burns Thomas Williamsold
- Burns Thomas Williamsold
- Burns Thomas Williamsold
- Burns Thomas Williamsold
- Burns Thomas Williamsold
41 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GKOS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
